Pulmonary Arterial Hypertension News and Research

RSS
Pulmonary arterial hypertension (PAH) is a condition involving high blood pressure and structural changes in the walls of the pulmonary arteries, which are the blood vessels that connect the right side of the heart to the lungs. Affecting people of all ages and ethnic backgrounds - but most commonly found in young women of child-bearing years - the disease has historically been chronic and incurable, with a poor survival rate. PAH is often not diagnosed in a timely manner because its early symptoms can be confused with those of many other pulmonary and respiratory conditions. Symptoms include shortness of breath, extreme fatigue, dizziness, fainting, swollen ankles and legs and chest pain (especially during physical activity). With proper diagnosis, there are currently several therapies to alleviate symptoms and improve quality of life for PAH patients. The key is to find a PAH specialist and pursue immediate treatment.
Study aims to elucidate the prevalence and etiology of PoPH in patients with chronic liver disease

Study aims to elucidate the prevalence and etiology of PoPH in patients with chronic liver disease

Algorithm accurately identifies pulmonary arterial hypertension in patients with scleroderma

Algorithm accurately identifies pulmonary arterial hypertension in patients with scleroderma

SARS-CoV-2 spike protein triggers cell signaling pathways in lung vascular cells

SARS-CoV-2 spike protein triggers cell signaling pathways in lung vascular cells

Virtual screening tool simplifies the process of diagnosing pulmonary hypertension

Virtual screening tool simplifies the process of diagnosing pulmonary hypertension

New approach to combination drug design could be applied to disease therapies beyond diabetes

New approach to combination drug design could be applied to disease therapies beyond diabetes

Researchers establish new 3D in vitro model for pulmonary arterial hypertension

Researchers establish new 3D in vitro model for pulmonary arterial hypertension

Fusion protein may help treat pulmonary arterial hypertension

Fusion protein may help treat pulmonary arterial hypertension

Molecular approach can improve diagnosis of pulmonary hypertension

Molecular approach can improve diagnosis of pulmonary hypertension

Sygnature Discovery supports New York Medical College pharmacologist in the fight against Covid-19

Sygnature Discovery supports New York Medical College pharmacologist in the fight against Covid-19

APEIRON Biologics launches clinical trial of respiratory drug to treat coronavirus infection

APEIRON Biologics launches clinical trial of respiratory drug to treat coronavirus infection

Gut bacteria may predict risk of pulmonary hypertension

Gut bacteria may predict risk of pulmonary hypertension

Specific gut bacteria may predict development of pulmonary arterial hypertension

Specific gut bacteria may predict development of pulmonary arterial hypertension

Hormone blocker shocker: Drug costs 8 times more when used for kids

Hormone blocker shocker: Drug costs 8 times more when used for kids

Advancing a protein drug in lettuce leaves to treat pulmonary arterial hypertension

Advancing a protein drug in lettuce leaves to treat pulmonary arterial hypertension

AI Therapeutics reports considerable progress on LAM-001 and LAM-004 clinical trials

AI Therapeutics reports considerable progress on LAM-001 and LAM-004 clinical trials

Study suggests antiarrhythmic drug as potential treatment for pulmonary arterial hypertension

Study suggests antiarrhythmic drug as potential treatment for pulmonary arterial hypertension

Newly identified antibody has potential to stop, reverse pulmonary arterial hypertension

Newly identified antibody has potential to stop, reverse pulmonary arterial hypertension

Scientists discover new drug target for fatal lung condition

Scientists discover new drug target for fatal lung condition

Tanner Pharma Group signs distribution agreement with MannKind Corporation

Tanner Pharma Group signs distribution agreement with MannKind Corporation

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.